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Abstract
Vaccine probe studies have emerged in the past 15 years as a useful way to characterise disease. 
By contrast, traditional studies of vaccines focus on defining the vaccine effectiveness or efficacy. 
The underlying basis for the vaccine probe approach is that the difference in disease burden 
between vaccinated and unvaccinated individuals can be ascribed to the vaccine-specific pathogen. 
Vaccine probe studies can increase understanding of a vaccine’s public health value. For instance, 
even when a vaccine has a seemingly low efficacy, a high baseline disease incidence can lead to a 
large vaccine-preventable disease burden and thus that population-based vaccine introduction 
would be justified. So far, vaccines have been used as probes to characterise disease syndromes 
caused by Haemophilus influenzae type b, pneumococcus, rotavirus, and early infant influenza. 
However, vaccine probe studies have enormous potential and could be used more widely in 
epidemiology, for example, to define the vaccine-preventable burden of malaria, typhoid, 
paediatric influenza, and dengue, and to identify causal interactions between different pathogens.
Introduction
Traditionally, vaccine studies have focused on characterising the vaccine’s efficacy. By 
contrast, vaccine probe studies characterise the disease. A vaccine probe study is a 
randomised clinical trial of a vaccine of known efficacy; the difference in the incidence of 
disease between vaccinated and unvaccinated people represents the vaccine-preventable 
disease incidence (VPDI). Vaccine probe studies also estimate the aetiological fraction (ie, 
the proportion of cases of a disease syndrome caused by the pathogen), which is often 
difficult to define through other study designs. Vaccines have already been used as probes to 
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characterise disease syndromes caused by Haemophilus influenzae type b (Hib), 
pneumococcus, influenza, and rotavirus. However, vaccine probe studies have much 
potential and could be used more widely in epidemiology, for example, to define the 
vaccine-preventable burden of malaria, and to clarify causal interactions between pathogens. 
This Review outlines the origin of these studies, provides examples of successful vaccine 
probe studies, and offers potential directions for future vaccine probe studies.
The origin of vaccine probe studies
Only in the past 15 years has the potential of vaccine trials to estimate disease burden been 
understood. The first trials to be interpreted in this way were ones assessing the 
effectiveness of conjugate vaccines against Hib.1,2 In the 1990s, the role of H influenzae in 
causing pneumonia was acknowledged, but the magnitude and type-specific burden 
remained unknown.3 A vaccine trial in Gambian infants4 showed an efficacy of 95% against 
culture-confirmed invasive Hib disease and 21% against all-cause radiologically confirmed 
pneumonia.2 The vaccine’s efficacy against pneumonia was much greater than expected and, 
together, these results supported the first introduction of Hib vaccine into the Expanded 
Program on Immunisation (EPI) in Africa in 1997. In Asia, however, most health ministries 
did not consider the incidence of paediatric Hib meningitis (usually <0.1 per 1000 person-
years) derived from prospective surveillance to be sufficient to justify introduction of Hib 
vaccine.5 By contrast, most Hib pneumonia episodes in Asia are non-bacteraemic and 
therefore invisible to normal clinical surveillance methods. This inability to easily diagnose 
Hib pneumonia generated an impasse whereby the investment case for Hib vaccine in Asia 
was contingent on an epidemiological parameter that could not easily be estimated.
The solution was to use the vaccine itself as a probe to reveal how much pneumonia could 
be prevented by Hib vaccine.6,7 The focus of this new trial was not vaccine efficacy, which 
was already well established, but the difference in pneumonia incidence between vaccinated 
and unvaccinated populations. This study, which took place in Lombok, Indonesia, was the 
first prospectively designed vaccine probe study. Subsequently, this approach of designing, 
or interpreting, vaccine studies from the perspective of disease effect has been used for 
several other vaccines.
Insights from vaccine probes
Vaccine probe studies yield three distinct insights into the epidemiology of vaccine-
preventable diseases. First, they can estimate the absolute burden of disease incidence that is 
preventable by a vaccine. Separate vaccine-preventable burden estimates can be calculated 
for different disease manifestations. For example, for pneumococcus and Hib, these include 
invasive disease, purulent meningitis, radiologically confirmed pneumonia, clinical 
pneumonia, otitis media, and death. The effect of a vaccine can also be measured against 
health-system endpoints such as health-care visits or drug use. Second, vaccine probe 
studies can measure the contribution of a specific pathogen to a broad clinical syndrome. For 
example, a vaccine could be used to estimate the proportion of cases of clinically defined 
pneumonia or culture-negative diarrhoea that are attributable to the pathogen targeted by 
vaccination. Third, vaccines can be used to investigate the causal chain in disease 
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pathogenesis. For example, if an infectious disease is hypothesised to cause a specific form 
of cancer, a trial of an effective vaccine against the infection could test the hypothesis.8
The epidemiological methods of vaccine probe studies do not differ from those of vaccine 
efficacy or effectiveness studies. Like vaccine efficacy studies, vaccine probe studies use 
randomised controlled trials and non-randomised designs,9 which measure disease incidence 
before and after vaccine introduction.10–13 In view of the similarity in methods, the probe 
approach can be incorporated into the design of a vaccine efficacy study (eg, the Indonesian 
Hib vaccine study) or it can be applied retrospectively or prospectively to studies designed 
primarily to measure vaccine efficacy.
How vaccine probe studies work
Three outcomes can be defined in a vaccine probe study: vaccine effectiveness or efficacy 
(VE); aetiological fraction; and VPDI. Assuming a controlled cohort study design, VE is 
defined as 1 minus (incidence in the vaccinated divided by incidence in the unvaccinated) 
and can be calculated for any disease syndrome for which incidence in vaccinated and 
unvaccinated populations is known. Aetiological fraction is defined as the syndrome-
specific VE divided by the VE for aetiologically confirmed cases. VPDI is calculated as 
incidence in the unvaccinated population minus the incidence in the vaccinated population, 
which is mathematically equivalent to the product of VE and incidence in the unvaccinated 
population. Therefore, VPDI is a combined measure of the ability of the vaccine to prevent 
disease and the preexisting disease burden.
An important notion in understanding how vaccine probe studies work is the specificity of 
clinical outcomes for the pathogen targeted by the vaccine. In the figure, the outcome that is 
most specific for the pneumococcus is blood culture-confirmed disease, but this represents 
only a small proportion of all pneumococcal pneumonia episodes because most bacterial 
pneumonias are non-bacteraemic.2,6,14,15 The proportion of pneumonia syndromes 
attributable to pneumococcus varies. Pneumococcus is assumed to cause all cases of culture-
confirmed pneumococcal pneumonia; vaccine probe study results suggest that 
pneumococcus causes a substantial proportion of radiologically confirmed pneumonia, a 
smaller proportion of severe, non-radiologically confirmed pneumonia, and a smaller 
proportion still of non-severe pneumonia. The most specific syndrome for pneumococcal 
disease (ie, culture-confirmed pneumonia) is used to estimate vaccine efficacy and by 
regulatory agencies for licensure on the assumption that vaccine efficacy remains relatively 
stable across populations. The remaining syndromes that are more sensitive for 
pneumococcal pneumonia provide more information about the overall preventable disease 
burden and hence the public health usefulness of a vaccine.
For a vaccine that is efficacious against pneumococcal disease, the measurable vaccine 
efficacy against highly specific outcomes such as culture-confirmed pneumonia will be high 
but it will be low against less specific outcomes (figure). Table 1 shows the numerical 
consequences of this difference and the results of a hypothetical probe study of a 
pneumococcal vaccine against pneumonia. The VE against aetiologically confirmed disease 
is 90%, suggesting the vaccine provides good individual protection—a regulatory 
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requirement for licensure of vaccines designed to provide direct protection. Despite the high 
VE in this case, however, the VPDI for this outcome is only 0.45 cases per 1000 person-
years. By contrast, the VPDI for all pneumonia is 4.5 per 1000 person-years, providing 
evidence for public health decision makers to introduce the vaccine, despite a VE for this 
outcome of only 9%. No minimum threshold of VPDI exists for decision makers to 
introduce vaccine; in addition to VPDI, this decision will depend on local priorities and 
additional concerns such as disease severity, long-term sequelae, duration of immunity, 
indirect protection provided to non-vaccinated groups, and vaccine cost.
To calculate a sample size in a prospectively designed probe study, some estimations of the 
VE and the incidence of the outcome are required. For example, in the Lombok Hib study,6 
although radiological pneumonia occurred at a lower incidence than all WHO-defined 
pneumonia, the expected VE for radiological pneumonia (20%) was higher than for all 
pneumonia (5%), requiring estimated sample sizes of 636 cases versus 7132 cases, 
respectively, to record a significant reduction in the vaccinated group. Thus, the size and 
cost of a probe study is affected by the primary endpoint of interest.
Examples of vaccine probe studies
Hib
Tables 2, 3, and 4 show the results of three large randomised controlled trials from The 
Gambia, Chile, and Indonesia. The Gambian study4 was a vaccine effectiveness study 
against pneumonia outcomes that laid much of the groundwork for later probe studies by 
assessing effectiveness against clinical syndromes. The Chile study16 was reinterpreted after 
implementation as a probe study. The Indonesian trial6 was the first study prospectively 
designed and interpreted as a probe study. For all three trials, the results showed that VE 
increased as the disease outcome became more specific for the aetiology prevented. In The 
Gambia and Chile, vaccine prevented more than 20% of radiologically confirmed 
pneumonia (or pneumonia with consolidation), whereas little prevention of this outcome 
was recorded in Indonesia. When comparing VPDI in Chile and Indonesia (The Gambia 
study did not report VPDI), the former found a maximum preventable incidence of 2.5 per 
1000 person-years for a composite clinical endpoint (conslidation, effusion, bronchial breath 
sounds, or increased erythrocyte sedimentation) whereas the Indonesian study found a 
maximum preventable incidence of 15.8 per 1000 person-years for clinical pneumonia, more 
than six-fold higher than in Chile.
Findings of the studies also showed geographical variations in the epidemiology of Hib 
pneumonia. In The Gambia, most cases of vaccine-preventable pneumonia had severe 
symptoms, whereas the opposite was true in Indonesia, where few cases of vaccine-
preventable Hib pneumonia had radiological abnormalities (such as lobar infiltrate or pleural 
effusion). These findings could point to earlier use of antibiotics, or to faster identification 
and referral of pneumonia cases.
For meningitis, the Indonesian trial showed a high VE but a low overall burden of 
aetiologically confirmed Hib disease. However, the vaccine probe study design showed a 
substantial burden of Hib meningitis that was not detected with standard laboratory 
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techniques. The VPDI for meningitis admission or clinic assessment for seizures was 1.6 per 
1000 person-years (95% CI 0.42–2.73).
Streptococcus pneumoniae—Pneumococcus is similar to Hib in that the largest burden 
of disease is non-bacteraemic pneumonia.14,15,19–21 Studies of pneumococcal vaccine also 
corroborate the finding that as the pathogen specificity of the disease outcome decreases, the 
VE falls, but the VPDI rises (table 5). Of five studies14,15,19,22,23,25 that used a WHO-
standardised radiological definition of obvious lobar pneumonia or pleural effusion,18 and 
also met the criteria for inclusion in a Cochrane review meta-analysis, the summary VE was 
27% (95% CI 15–36%, intention-to-treat analysis of HIV-negative children <24-months-
old).14,15,19,22–25 The range of VEs (16–35%) in these studies was narrow. VPDI, on the 
other hand, varied widely by site, and was proportional to the baseline incidence; pneumonia 
reductions in rural Gambia (23.2 per 1000 person-years) were more than ten times greater 
than in the USA (1.6 per 1000 person-years). For four studies that measured the less specific 
outcome of clinical pneumonia,14,15,19,22,25 the VE ranged from 6% to 7% across three 
studies and was less than 0% in the fourth.24
The vaccine probe approach provides a minimum estimate of aetiological fraction of 
pneumonia caused by the serotypes of pneumococcus included in the vaccine. In the per-
protocol analysis of the trial in The Gambia, the measured VE for radiologically confirmed 
pneumonia was 37%, suggesting that at least a third of all pneumonia episodes are caused by 
the nine serotypes of pneumococci included in the vaccine.14 In participants who received a 
placebo, the proportion of culture-positive episodes of radiologically confirmed pneumonia 
that was caused by vaccine serotypes was 58% (26 of 45 cases). If this accurately shows the 
vaccine serotype coverage of non-bacteraemic episodes, then a similar vaccine, with 100% 
VE against all serotypes, would have prevented 64% (ie, 37% divided by 58%) of 
radiologically confirmed pneumonia cases. The actual efficacy of the vaccine against 
pneumococcal pneumonia is unknown, but it is unlikely to exceed the measured VE against 
vaccine-type invasive pneumococcal disease (77%), because mucosal disease probably 
needs higher antibody concentrations for protection than invasive disease.26,27 On this basis, 
a vaccine would have prevented at least 83% (ie, 64% divided by 77%) of all cases of 
radiologically confirmed pneumonia, implying that four-fifths of all radiologically 
confirmed pneumonia was caused by Streptococcus pneumoniae in the specific context of 
The Gambia, which had high and sustained Hib vaccine coverage at the time.
One other unique aspect of this trial was its ability to probe mortality from pneumococcal 
disease.14,21 The VE against all-cause mortality in the trial was 16% (95% CI 3–28%) 
among children aged 6 weeks to 2 years, translating into a vaccine-preventable mortality 
reduction of 5 per 1000 person-years.14 The extent of the potential mortality reduction in 
this setting was not known before this vaccine probe analysis.
Influenza
In a non-randomised probe study in pilgrims attending the Hajj in Mecca,9 participants 
chose whether or not to receive the influenza vaccine, and the study documented the 
presence of influenza-like illness, other respiratory symptoms, and drug use during the Hajj. 
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The unadjusted attack rates (the cumulative incidence of infection in a group of people 
during a period of time), for influenza-like illness among unvaccinated and vaccinated 
pilgrims were 62% and 36%, respectively, during the Hajj. The adjusted VE was 38%, 
suggesting that at least 38% of influenza-like illness episodes were caused by influenza 
virus. Overall, the influenza vaccine prevented 220 cases of influenza-like illness, 170 
courses of antibiotics, and 230 courses of cold drug use per 1000 pilgrims.
A review of split-virion influenza vaccine studies estimated VPDIs by multiplying VE by 
the incidence or attack rate among the unvaccinated population.28 The review showed that 
four studies of working age adults, which used relatively similar case definitions, reported 
VEs that varied widely from 25% to 80%. At the same time, the range for VPDI was narrow 
at 209–350 per 1000 people per year or per influenza season. Similarly, three studies found 
VEs of 36–84% against workplace absenteeism, but found similar VPDIs of 530–740 days 
per 1000 persons per year or per influenza season. One potential explanation for these 
results is that although influenza incidence was similar across study sites (leading to similar 
VPDIs), the incidence of non-influenza causes of the same clinical syndrome, such as 
respiratory syncytial virus, parainfluenza virus and rhinovirus, led to varying VEs. In 
another study29 that tested whether influenza vaccine could reduce major cardiac events in 
people aged 50 years or older with previous acute coronary syndrome, researchers recorded 
a VPDI of 97 per 1000 people per year (value calculated subsequently, because investigators 
did not directly report this result).
In a study30 comparing influenza versus 23-valent pneumococcal polysaccharide 
vaccination given to pregnant women in Bangladesh, receipt of influenza vaccine prevented 
29% more respiratory illnesses with fever episodes and 42% more clinic visits through age 6 
months in children born to vaccinated women.
Rotavirus
Findings of a probe analysis13 using a cohort design of the Rotashield rotavirus vaccine in 
the USA showed that up to 85% of gastroenteritis hospital admissions in young children 
were due to rotavirus, compared with estimates of 48–53% from surveillance. The first year 
of national rotavirus vaccine use in Finland showed that the VPDI for all-cause acute 
gastroenteritis (10.7 per 1000 person-years) was 2.7 times greater than the VPDI for 
laboratory-confirmed rotavirus acute gastroenteritis (3.9 per 1000 person-years) in children 
aged younger than 1 year.31
In resource-poor settings where access to health care is restricted, and also where most 
gastroenteritis deaths happen, it is crucial to define disease burden accurately to prioritise 
scarce resources.32 In a trial of pentavalent rota virus vaccine in rural Kenya, the VE against 
severe rotavirus gastro enteritis presenting at a health facility in the first year of life was 
84%, and 33 cases were prevented per 1000 person-years.33,34 By contrast, through active 
monthly follow-up of the same study children at home, the VE against all-cause 
gastroenteritis with severe dehydration was just 34%, consistent with another study in South 
Africa.34,35 The aetiological fraction for rotavirus in community based cases of severe 
diarrhoea in infancy can be estimated as VE against all-cause gastro enteritis with severe 
dehydration (34%) divided by VE against rotavirus-confirmed severe gastroenteritis (84%), 
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or 40%. The study also estimated VPDI among children in the community as 190 per 1000 
person-years in the first year of life, six times higher than in children presenting to health-
care facilities. This finding shows that VPDI for outcomes dependent on access to care can 
vary across settings because the use of health-care facilities varies.
Vaccine probes to define interactions in disease causality
Vaccine probe studies can be used to test causality in disease. For example, malaria has been 
postulated to induce haem oxygenase, which limits the production of bactericidal reactive 
oxygen species, increasing susceptibility to intracellular bacterial diseases such as non-
typhoid Salmonella.36 A vaccine that effectively reduces infection with Plasmodium 
falciparum could be used to test this hypothesis directly in a trial in which the intervention 
was malaria vaccine and the outcome was invasive salmonella disease.
Epidemiological and laboratory evidence suggests that infection with influenza virus is 
followed, after a short interval, by an increased susceptibility to bacterial pneumonia, 
especially that due to pneumococcus or Staphylococcus aureus.37–40 The causal nature of 
this association, and the magnitude of the effect, could be confirmed and measured in a 
vaccine probe study of an effective influenza vaccine in which the outcome is culture-
confirmed bacterial pneumonia. The pathogenesis of both diseases shares common 
characteristics and so they might be acting sim ultaneously to cause one disease episode.41 
In this hypothesis, the efficacy of a vaccine against pneumococcal pneumonia would differ 
between influenza-exposed and influenza-unexposed pop ulations. The statistical test of the 
hypothesis, in the analysis of pneumococcal disease, would be the interaction between 
influenza infection and vaccination status. Researchers exploring these mechanisms have not 
usually tested such interaction, probably because most primary vaccine studies are only 
powered to examine main effects.38,42,43 When designing vaccine probe studies that are 
intended to test the disease consequences of pathogen infection, the key point is to specify 
the causal model under investigation at the outset, and select the appropriate vaccine 
intervention and analysis to match that hypothesis.
Challenges in the design and interpretation of vaccine probe studies
The major assumption of vaccine probe studies in estimating the aetiological fraction of a 
pathogen is that a reasonable estimate of true VE exists. This value can be obtained from a 
previous study or from a nested study of VE against microbiologically confirmed outcomes 
during the course of the probe study of a broader outcome. Nested studies have the 
advantage that they control for variability in vaccination conditions, such as cold chain 
integrity, and population characteristics (eg, HIV prevalence). In vaccines in which VE 
varies each year depending on the antigenic match, such as for influenza, a nested study is 
needed. The measured VE for a microbiologically confirmed endpoint might not represent 
the true VE for a broader endpoint. Unlike VPDI, measuring aetiological fraction requires an 
estimate of VE against aetiologically confirmed disease. It also assumes that this measured 
VE is equivalent to the VE against non-aetiologically confirmed disease. If the VE against 
aetiologically confirmed disease is greater than that against disease truly due to a pathogen, 
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but that remains aetiologically non-confirmed (such as non-bacteraemic Hib or 
pneumococcal pneumonia), the aetiological fraction will be underestimated, and vice versa.
By contrast, VE is not needed to estimate VPDI—the amount of disease prevented by the 
vaccine is a simple subtraction of rates. The true incidence of the target disease is given as 
the VPDI divided by VE, but for the purposes of public health policy, the VPDI alone is 
most important because it shows the amount of disease preventable by vaccination. Hence, 
even a vaccine with a low VE can be of public health interest if the disease it targets has a 
high background incidence, such as happened during assessment of the RTS,S malaria 
vaccine.44,45 Similarly, because VE might be related to the force of infection, the VE could 
be lower in a high incidence than in a low incidence setting, whereas the VPDI would be 
greater in the high incidence setting, as was shown with rotavirus vaccines.34,35
In some vaccine trials, the first event of a disease is specified as the primary outcome 
measure;14,15,33,35 this is useful for measuring vaccine performance for regulatory purposes 
because people who have recurrent events can have substantially different vaccine 
responses. However, first-event analyses, by definition, can only estimate the VPDI or 
aetiological fraction of first disease episodes and will underestimate the disease burden if the 
pathogen causes recurrent vaccine-preventable episodes, even if the VE against recurrent 
episodes is lower. Additionally, first and subsequent disease episodes incur similar public 
health costs, and so it would be relevant to include recurrent episodes when investigating the 
full public health effect of a vaccine.46 Similarly, vaccine probe studies should use an 
intention-to-treat rather than per-protocol analysis because intention-to-treat provides a 
realistic estimate of VPDI that accounts for imperfect vaccine delivery.
Vaccines can also have a substantial positive effect on the unvaccinated population by 
reducing pathogenic transmission. For some vaccines, such as pneumococcal conjugate 
vaccine, this indirect or so-called herd protection can prevent more cases in the population 
than the direct protective effect.47 For a vaccine with important indirect effects, the estimate 
of VPDI should incorporate both direct and indirect protection by using a cluster-
randomised trial design. This was the approach taken by the Indonesian Hib vaccine study.6 
An individually randomised design would have compared the combination of direct and 
indirect effects with indirect effects alone; if indirect effects were high, such a study might 
find no additional benefit to the vaccinated group.
The interpretation of probe studies relies on the assumption that the vaccine does not prevent 
disease other than that caused by the target organism. However, rotavirus vaccine might 
prevent other viral gastroenteritis causes, such as adenovirus and sappovirus.13 Moreoever, 
some researchers have postulated that some vaccines have non-specific immune-modulating 
effects.48 These non-specific vaccine effects would not alter estimates of the VPDI for a 
clinical syndrome, but would lead to erroneous estimates of the pathogen-specific 
aetiological fraction.
Probe studies are subject to the same design issues as other vaccine studies, including 
selection bias and confounding. As in studies to establish VE, study limitations tend to be 
greater with non-randomised designs. In investigations before and after vaccine 
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introduction, factors other than vaccine introduction, such as secular trends in rates of 
hospital admission or mortality, can affect the estimate of disease burden, and thus 
inaccurately estimate VPDI. This bias can be measured by studying a comparison disease, 
not affected by vaccine, but with similar epidemiology and disease presentation (eg, 
following pneumococcal meningitis in a Hib vaccine study).
VE against aetiologically confirmed disease is normally similar across different populations 
and time periods, although rotavirus vaccine is an exception with lower VE in low-income 
populations.34,35 By contrast, VE against non-aetiologically confirmed disease syndromes 
and aetiological fraction both vary with fluctuations in the epidemiology of other aetiologies 
causing the syndrome. However VPDI varies with aetiology-specific disease incidence, and 
so might be a more appropriate measure to compare vaccine effect across study sites than 
aetiological fraction or VE for non-aetiologically confirmed disease outcomes. Both VPDI 
and aetiological fraction can vary by patient age as immune response and disease 
epidemiology change, as well with vaccine formulation. For example, 13-valent 
pneumococcal conjugate vaccine shows higher VPDI and aetiological fraction than 7-valent 
vaccine, in settings in which the additional serotypes cause disease.
Ethical considerations
Incorporating an assessment of VPDI or aetiological fraction into a study that is 
prospectively designed to measure vaccine efficacy does not generally present ethical 
problems. However, if a study is designed from inception as a randomised controlled trial to 
estimate VPDI, then the ethical justification needs careful consideration because some 
participants would be randomly assigned not to receive a vaccine, even though it is known 
to be effective. Thus, from the point of view of the vaccinated individual, vaccine probe 
studies with a randomised design might only be regarded as ethically justified if insufficient 
evidence exists of the disease burden to predict whether the vaccine will provide a sufficient 
marginal benefit to the trial participant.
However, the level of individual marginal benefit sufficient to preclude a randomised 
controlled trial is difficult to define. For example, even if existing disease burden data 
suggest a small individual benefit from vaccination, there might be insufficient data to 
justify the introduction of the vaccine at population level. This argument has allowed some 
ethical committees to justify randomised trials to document VPDI in a particular setting 
considering vaccine use.6 However, randomised trials to define VPDI should not delay 
vaccine introduction when the disease risk in both the individual and population are known, 
and recommendations for universal vaccine implementation exist.49
Use of the VPDI to develop public health messages presents some challenges. Parents might 
care most about whether a particular vaccine will protect their own child, as shown by the 
VE (against either aetiologically confirmed or non-aetiologically confirmed disease), rather 
than total preventable burden. Consequently, the communication of the results of vaccine 
probe studies, including their role in developing models for burden of disease and health 
economics, could be most effective when aimed at public health decision makers and 
funders.
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Future vaccine probe studies
There are several areas where vaccine probe studies could be useful in the future. Influenza 
is a difficult infection to study with conventional methods. Influenza can cause 
asymptomatic disease, interact with other causes of respiratory disease, be undetectable by 
the time a person presents at a health-care facility, even if the virus was in the causal chain 
of infection, and might not be detectable through diagnostic tests. Every year, a vaccine is 
formulated to target circulating strains, and these vaccines could be incorporated into probe 
studies to overcome these challenges in understanding influenza burden, and help estimate 
the public health benefit of immunisation. Influenza vaccine probe studies have unique 
issues in that they need to take into account seasonal and yearly fluctuations in overall and 
vaccine type disease, and the contribution of influenza in causing pneumonia, which can 
vary in tropical versus subtropical areas.50,51
The most important clinical outcome of rubella infection is congenital rubella syndrome. 
Although typically characterised by cataracts, congenital heart disease, and hearing 
impairment, the potential consequences of intrauterine rubella infection are much broader. A 
well-designed maternal immunisation trial could define the VPDI of rubella-associated 
stillbirth and congenital anomalies.
In studies of the RTS,S malaria vaccine, with patients followed-up for 12 months and 
receiving three vaccine doses at monthly intervals, VE against severe malaria was 37% for 
infants enrolled at 6 to 12 weeks of age and 47% for toddlers enrolled at 5 to 17 months of 
age.44,45 However, the VPDI for severe malaria could be estimated from the results as 9 per 
1000 person-years for infants and 23 per 1000 person-years for toddlers. Although the 
vaccine efficacy might seem low, assuming that it is sustained over time, the VPDI means 
that the public health value of this vaccine’s direct effects could be judged to be as high as 
that of other new childhood vaccines, such as Hib and pneumococcal vaccines. A vaccine 
probe approach for a malaria vaccine also could assess the contribution of malaria to non-
specific child-health outcomes such as anaemia, growth, neurological development, and 
invasive bacterial infections, including salmonellosis.52
Although probe studies in low-income countries have focused on the preventable burden of 
severe disease and death, more probe studies could be undertaken in high-income countries 
focusing on vaccine preventable health system and economic outcomes, such as drug use 
and hospital utilisation.8
Conclusions
Vaccine probe studies have been used successfully to provide disease burden data to support 
public health decision making for Hib, pneumococcal, influenza, and rotavirus vaccines. The 
tremendous investment in vaccines by the GAVI Alliance, extending coverage of existing 
vaccines and introducing a broad array of new vaccines, has focused public health attention 
on assessing the value of vaccines. This approach goes beyond the demonstration of VE to 
the measurable effect of vaccines in the population. Vaccine probe studies directly support 
this approach, and could be used more widely. First, the public health usefulness of VE trial 
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results could be greatly enhanced by adding the outcomes of VPDI and aetiological fraction 
to existing analysis plans. Moreover, VE studies of new vaccines should be designed from 
inception to capture common clinical and non-specific public health outcomes, even if the 
VE is expected to be moderate. Second, vaccine probe studies could be designed 
prospectively to estimate the disease burden of common vaccine-preventable diseases. 
Third, the vaccine probe approach could be used more widely to define the role of pathogens 
in causing disease. Vaccine probe studies are unique methods to reveal the biological role of 
a pathogen and the public health importance of a vaccine.
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Search strategy and selection criteria
Studies for inclusion were identified through PubMed searches for articles published 
between Jan 1, 1990, and Dec 31, 2013, in any language using the following terms: 
(“vaccine probe” or “probe study”) and (“Haemophilus influenzae type b” or “Hib” or 
“Streptococcus pneumoniae” or “pneumococcus” or “rotavirus” or “influenza”). This 
search yielded only a few references presumably because so few studies have been 
prospectively designed as probe studies. We augmented the search using references of 
identified articles and other studies known to the investigators. We included articles that 
reported or allowed calculation of vaccine-preventable disease incidence or aetiological 
fraction identified by vaccination.
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Figure. Proportions of different categories of pneumonia attributable to pneumococcus (left) and 
the effect of pneumococcal vaccine (right)
On the left, for the more specific outcomes towards the top of the triangle, vaccine efficacy 
is higher, whereas for the more sensitive outcomes at the base of the triangle, the vaccine 
preventable disease incidence is higher, as is the public health utility of vaccine.
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Table 2
Haemophilus influenzae type b vaccine effectiveness against non-microbiological pneumonia outcomes in The 
Gambia2,4 in children from first vaccination to 5–36 months after first vaccination
Number vaccinated Number of controls VE (%)
Cough with fast breathing or chest-wall indrawing 873 913   4.4%
Lower chest-wall indrawing 436 466   6.5%
Any obvious radiological infiltrate 198 251 21%*
Radiological consolidation or effusion   88 115 25%*
VE=Vaccine effectiveness. Most of the cases were admitted to hospital. Vaccine-preventable disease incidence was not calculated in the published 
papers for this study.
*
VE has 95% CIs that exclude 0.
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Table 3
Haemophilus influenzae type b vaccine-preventable disease incidence for children admitted to hospital with 
pneumonia in Chile16,17
Control incidence* VE (%) VPDI*†
Radiological consolidation, effusion, bronchial breath sounds, or raised ESR 9.7 26%‡ 2.5
Radiological consolidation or effusion 5.0 22% 1.1
VE=Vaccine effectiveness. VPDI=vaccine-preventable disease incidence. ESR=erythrocyte sedimentation rate.
*
All incidences are per 1000 person-years of follow-up.
†
VPDI is calculated as vaccine effectiveness multiplied by control group incidence, and is shown per 1000 person-years of follow-up in children 
from age of first vaccination to age 2 years.
‡
VE has 95% CIs that exclude 0.
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Table 4
Hib vaccine-preventable disease incidence for pneumonia and meningitis in Indonesia6
Control incidence* VE (%) VPDI*†
Pneumonia outcomes
Clinical pneumonia 395   4.0%‡ 15.8
Hospital admission or clinical assessment of severe pneumonia   54.6   4.8%   2.6
Hospital admission for severe pneumonia   45.2   3.8%   1.7
Radiological consolidation or pleural effusion with WHO criteria18     8.9 −4.9% −0.43
Meningitis outcomes
Hospital admission for meningitis or clinic assessment for seizures     7.0 22%‡   1.6
Hospital admission for meningitis     5.4 16%   0.87
Probable bacterial or confirmed Hib     0.86 55%‡   0.47
Microbiologically confirmed Hib     0.19 86%‡   0.16
Hib=Haemophilus influenzae type b. VE=Vaccine effectiveness. VPDI=vaccine-preventable disease incidence.
*
All incidences are per 1000 person-years of follow-up.
†
VPDI is calculated as the vaccine effectiveness multiplied by the control group incidence, and is shown per 1000 person-years of follow-up in 
children from age of first vaccination to age 2 years.
‡
VE has 95% CIs that exclude 0.
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